Pharmaceutical Benefits Advisory Council responds to criticism Chair Andrew Wilson said suggestions of delayed approvals are not new and Australia has one of ‘the fastest systems in the world’.
GPs should be able to see their billing against national averages: RACGP President Dr Harry Nespolon believes such a change would help to ensure GPs are billing correctly.
NDIS underspend continues The Government has now spent $4.6 billion less on the scheme than originally anticipated, with the savings put towards the Budget bottom line.
NDIS review to streamline processes The Federal Government has announced a thorough assessment of the scheme, designed to cut red tape and reduce wait times.
Cancer and inflammatory disease medicines receive $56 million boost Four new medicines will be listed through the Pharmaceutical Benefits Scheme, helping patients fight aggressive cancers and inflammatory conditions.
New resource to foster patients’ financial health literacy A new RACGP-endorsed guide aims to help patients understand health costs and empower their discussions around medical fees.
Access to cystic fibrosis medication expanded Children aged 12–24 months with a rare form of the genetic disorder will soon be eligible to receive subsidised medication, saving their families up to $300,000 per year.
GPs’ role in linking patients with the NDIS The new RACGP resource can help assess patient eligibility for the NDIS and give information on how to access it.
How are GPs finding the MBS changes for thoracic medicine? The Department of Health and the RACGP ask how changes to items for respiratory function tests and sleep studies are affecting general practice.
Reducing value disparity in the MBS The RACGP has reiterated its support for time-tiered items for other medical specialists, and the simplification of case conferencing items.